Compare AbbVie Inc (ABBV) vs JetBlue Airways Corporation (JBLU) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

JetBlue (JBLU) trades at $6.07, down 1.94% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a Q2 2026 earnings beat but continues to post net losses, with negative profit margins and declining revenue trends. Recent news includes analyst downgrades from Citigroup citing geopolitical risks, though the company has introduced new fare structures and lounge enhancements to drive growth.

The outlook remains challenging with persistent losses and high debt levels, though cost management and strategic initiatives offer potential upside. Key risks include fuel cost volatility, competitive pressures, and execution of the 2028 profit target. Analyst consensus is cautious with a $5.18 price target below current levels, reflecting skepticism about near-term profitability.